Evidence map›Paper›PMID 27568520›Full record

ArticleLeukemia2017

Loss of PRDM1/BLIMP-1 function contributes to poor prognosis of activated B-cell-like diffuse large B-cell lymphoma.

Y Xia, Z Y Xu-Monette, A Tzankov, X Li, G C Manyam, V Murty, G Bhagat, S Zhang, L Pasqualucci, C Visco and 23 more

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Leukemia, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 43 papers.

0numbers the graph read from it
0cells of the map it votes in
43citing papers in PubMed
4.9field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

43 citing papers in PubMed, 61 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Review
  5. Article
  6. Review
  7. Review
  8. Article
  9. Article
  10. Review
  11. Article
  12. Article
  13. Review
  14. Review
  15. Review
  16. Article
  17. Article
  18. Review
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

33 authors at 20 institutions in 9 countries.

Y XiaDepartment of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Z Y Xu-MonetteDepartment of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
A TzankovUniversity Hospital, Basel, Switzerland.
X LiDepartment of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
G C ManyamDepartment of Bioinformatics and Computational Biology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
V MurtyColumbia University Medical Center and New York Presbyterian Hospital, New York, NY, USA.
G BhagatColumbia University Medical Center and New York Presbyterian Hospital, New York, NY, USA.
S ZhangDepartment of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
L PasqualucciColumbia University Medical Center and New York Presbyterian Hospital, New York, NY, USA.
C ViscoSan Bortolo Hospital, Vicenza, Italy.
K DybkaerAalborg University Hospital, Aalborg, Denmark.
A ChiuMemorial Sloan-Kettering Cancer Center, New York, NY, USA.
A OraziWeill Medical College of Cornell University, New York, NY, USA.
Y ZuThe Methodist Hospital, Houston, TX, USA.
K L RichardsCornell University, Ithaca, NY, USA.
E D HsiCleveland Clinic, Cleveland, OH, USA.
W W L ChoiUniversity of Hong Kong Li Ka Shing Faculty of Medicine, Hong Kong, China.
J H van KriekenRadboud University Nijmegen Medical Centre, Nijmegen, Netherlands.
J HuhAsan Medical Center, Ulsan University College of Medicine, Seoul, South Korea.
M PonzoniSan Raffaele H. Scientific Institute, Milan, Italy.
A J M FerreriSan Raffaele H. Scientific Institute, Milan, Italy.
M B MøllerOdense University Hospital, Odense, Denmark.
B M ParsonsGundersen Lutheran Health System, La Crosse, WI, USA.
J N WinterFeinberg School of Medicine, Northwestern University, Chicago, IL, USA.
M A PirisHospital Universitario Marqués de Valdecilla, Santander, Spain.
J WestinDepartment of Lymphoma/Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
N FowlerDepartment of Lymphoma/Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
R N MirandaDepartment of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
C Y OkDepartment of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Y LiDepartment of Cancer Biology, Lerner Research Institute, Cleveland Clinic, Cleveland, OH, USA.
J LiThe First Affiliated Hospital of Nanjing Medical University, Jiangsu Province Hospital, Nanjing, China.
L J MedeirosDepartment of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
K H YoungDepartment of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
The University of Texas MD Anderson Cancer Center · USCornell University · USNew York Hospital Queens · USSan Raffaele University of Rome · ITAalborg University Hospital · DKAsan Medical Center · KRCleveland Clinic · USCleveland Clinic Lerner College of Medicine · USColumbia University Irving Medical Center · USGundersen Health System · USJiangsu Province Hospital · CNMarqués de Valdecilla University Hospital · ESMemorial Sloan Kettering Cancer Center · USMethodist Hospital · USNanjing Medical University · CNNorthwestern University · USOdense University Hospital · DKOspedale San Bortolo · ITRadboud University Medical Center · NLUniversity Hospital of Basel · CH

Funding

Tumor Evolution and Metastasis ProgramP30CA016672 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI Fabien Delerue · 1985 to 2026
$290.8M
Tissue ResourceP50CA126752 · NCI · BAYLOR COLLEGE OF MEDICINE · PI Leonid S Metelitsa · 2007 to 2026
$51.4M
P4 -TARGETING MULTIPLE MYELOMA BY COMBINING CDK INHIBITORS AND BCL-2 ANTAGONISTSP50CA142509 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI KWAK, LARRY W · 2010 to 2014
$11.1M
Convergence of MicroRNAs and p53 Signaling in Multiple Myeloma: Environmental CoR01CA138688 · NCI · UNIVERSITY OF LOUISVILLE · PI LI, YONG · 2009 to 2017
$2.9M
UT M.D. Anderson Cancer Center Lymphoma SPOREP50CA136411 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI YOUNES, ANAS · 2009 to 2011
$1.5M
Deep Sequencing of Small Regulatory RNAs in Diffuse Large B cell LymphomaRC1CA146299 · NCI · SCRIPPS RESEARCH INSTITUTE, THE · PI XIAO, CHANGCHUN · 2009 to 2010
$1000k
NCI NIH HHS P30 CA016672NCI NIH HHS P50 CA126752NCI NIH HHS P50 CA136411NCI NIH HHS P50 CA142509NCI NIH HHS R01 CA138688NCI NIH HHS RC1 CA146299
6 · The paper itself

Abstract

PRDM1/BLIMP-1, a master regulator of plasma-cell differentiation, is frequently inactivated in activated B-cell-like (ABC) diffuse large B-cell lymphoma (DLBCL) patients. Little is known about its genetic aberrations and relevant clinical implications. A large series of patients with de novo DLBCL was effectively evaluated for PRDM1/BLIMP-1 deletion, mutation, and protein expression. BLIMP-1 expression was frequently associated with the ABC phenotype and plasmablastic morphologic subtype of DLBCL, yet 63% of the ABC-DLBCL patients were negative for BLIMP-1 protein expression. In these patients, loss of BLIMP-1 was associated with Myc overexpression and decreased expression of p53 pathway molecules. In addition, homozygous PRDM1 deletions and PRDM1 mutations within exons 1 and 2, which encode for domains crucial for transcriptional repression, were found to show a poor prognostic impact in patients with ABC-DLBCL but not in those with germinal center B-cell-like DLBCL (GCB-DLBCL). Gene expression profiling revealed that loss of PRDM1/BLIMP-1 expression correlated with a decreased plasma-cell differentiation signature and upregulation of genes involved in B-cell receptor signaling and tumor-cell proliferation. In conclusion, these results provide novel clinical and biological insight into the tumor-suppressive role of PRDM1/BLIMP-1 in ABC-DLBCL patients and suggest that loss of PRDM1/BLIMP-1 function contributes to the overall poor prognosis of ABC-DLBCL patients.

Indexed as

MutationAdolescentAdultAgedAged, 80 and overAntineoplastic Combined Chemotherapy ProtocolsBiomarkers, TumorBiopsyFemaleFollow-Up StudiesGene Expression ProfilingGene Expression Regulation, NeoplasticHumansLymphoma, Large B-Cell, DiffuseMaleMiddle AgedBiomarkers, TumorPositive Regulatory Domain I-Binding Factor 1PRDM1 protein, humanRepressor Proteins

Identifiers

PMID27568520
PMCPMC5837859
OpenAlexW2510496497

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.